Skip Navigation

The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec VB-111 Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Brief Summary

Type:
Ovarian

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03398655

Study #:
STUDY00143198

Start Date:
Jul 24, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03398655

View Complete Trial Details & Eligibility at ClinicalTrials.gov